Glycerophospho-N-Oleoyl Ethanolamine
mRNA synthesis
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
Tyramide Signal Amplification (TSA)
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Phos Binding Reagent Acrylamide
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
Cell Counting Kit-8 (CCK-8)
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
SYBR Safe DNA Gel Stain
Safe and sensitive stain for visualization of DNA or RNA in agarose or acrylamide gels.
Inhibitor Cocktails
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
Glycerophospho-N-Oleoyl Ethanolamine is the precursor of oleoyl ethanolamide (OEA). The fatty-acid ethanolamide, oleoylethanolamide (OEA) is a naturally occurring lipid. Oleoylethanolamide is an endogenous PPAR-α agonist. Oleoylethanolamide has been involved in modulating feeding and energy homeostasis by binding to peroxisome proliferator-activated receptor-alpha (PPAR-α) [1]. PPAR-α is a transcription factor and a major regulator of lipid metabolism in the liver. Activation of PPAR-α is mainly involved in fatty acid oxidation and expressed in liver, kidney, and skeletal muscle. Through ligand binding, PPAR-α promotes uptake, utilization, and catabolism of fatty acids [2].
OEA reduced food intake and lowered body-weight gain. Subchronic OEA treatment (5 mg/kg, i.p., once daily for two weeks) in Zucker rats initiated transcription of PPAR-α and other PPAR-α target gene [1]. OEA is an endogenous, potent agonist for PPARα. OEA activated PPARα with an EC50 value of 120 nM in a transactivation assay [3]. In rodents, intraperitoneal administration of OEA induced satiety and peripheral utilization of lipid substrate. Acute oral administration induced satiety [4].
References:
[1] Fu J, Oveisi F, Gaetani S, et al. Oleoylethanolamide, an endogenous PPAR-α agonist, lowers body weight and hyperlipidemia in obese rats[J]. Neuropharmacology, 2005, 48(8): 1147-1153.
[2] Schiffrin E L, Amiri F, Benkirane K, et al. Peroxisome proliferator-activated receptors[J]. Hypertension, 2003, 42(4): 664-668.
[3] Fu J, Gaetani S, Oveisi F, et al. Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-α[J]. Nature, 2003, 425(6953): 90-93.
[4] Thabuis C, Destaillats F, Tissot‐Favre D, et al. Oleoyl‐ethanolamide (OEA): A bioactive lipid derived from oleic acid and phosphatidylethanol‐amine[J]. Lipid Technology, 2007, 19(10): 225-227.
Physical Appearance | A crystalline solid |
Storage | Store at -20°C |
M.Wt | 479.6 |
Cas No. | 201738-24-1 |
Formula | C23H46NO7P |
Solubility | ≤20mg/ml in ethanol;20mg/ml in DMSO;20mg/ml in dimethyl formamide |
Chemical Name | mono(2,3-dihydroxypropyl)-mono[2-[[(9Z)-1-oxo-9-octadecenyl]amino]ethyl] ester phosphoric acid |
SDF | Download SDF |
Canonical SMILES | CCCCCCCC/C=C\CCCCCCCC(=O)NCCOP(=O)(O)OCC(O)CO |
运输条件 | 蓝冰运输或根据您的需求运输。 |
一般建议 | 不同厂家不同批次产品溶解度各有差异,仅做参考。若实验所需浓度过大至产品溶解极限,请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存,请尽快用完。 |